Pharsight

1. List of Aldara drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7696159	BAUSCH	Treatment for basal cell carcinoma	Apr, 2024 (1 year, 1 month from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7696159 (Pediatric)	BAUSCH	Treatment for basal cell carcinoma	Oct, 2024 (1 year, 7 months from now)

Market Authorisation Date: 27 February, 1997

Treatment: Treatment of biopsy-confirmed, primary superficial basal cell carcinoma (sbcc); Works through the induction of interferon and other cytokines

Dosage: CREAM;TOPICAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
0.05	17 Oct, 2006	1	25 Feb, 2010	24 Aug, 2010	Eligible

Strength	Dosage	Availability
5%	CREAM;TOPICAL	Prescription

2. List of Zyclara drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8598196	BAUSCH	Methods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of imiquimod therapy	Aug, 2029 (6 years from now)
US10238645	BAUSCH	Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts	Aug, 2029 (6 years from now)
US10238644	BAUSCH	2×2×2 week dosing regimen for treating acting keratosis with pharmaceutical compositions formulated with 3.75% imiquimod	Dec, 2029 (6 years from now)
US11318130	BAUSCH	2x2x2 week dosing regimen for treating actinic keratosis with pharmaceutical compositions formulated with 3.75% imiquimod	Dec, 2029 (6 years from now)
US8236816	BAUSCH	2×2×2 week dosing regimen for treating actinic keratosis with pharmaceutical compositions formulated with 3.75 % imiquimod	Dec, 2029 (6 years from now)
US8222270	BAUSCH	2×2×2 week treatment regimen for treating actinic keratosis with pharmaceutical compositions formulated with 2.5% imiquimod	Dec, 2029 (6 years from now)
US8299109	BAUSCH	Method of treating actinic keratosis with 3.75% imiquimod cream	Dec, 2029 (6 years from now)
US10918635	BAUSCH	Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts	Apr, 2030 (7 years from now)
US11202752	BAUSCH	Methods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of imiquimod therapy	Apr, 2030 (7 years from now)

Market Authorisation Date: 25 March, 2010

Treatment: Treatment of genital warts; Treatment of perianal warts; Treatment of actinic keratosis

Dosage: CREAM;TOPICAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
0.025	17 Jun, 2014	1		11 Dec, 2029
0.0375	08 Aug, 2012	1		11 Dec, 2029	Non-Forfeiture

Strength	Dosage	Availability
2.5%	CREAM;TOPICAL	Prescription
3.75%	CREAM;TOPICAL	Prescription

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in

Drugs that contains Inclisiran Sodium